<DOC>
	<DOCNO>NCT00461500</DOCNO>
	<brief_summary>This study compare 12 week , two treatment strategy Initial Maintenance Therapy : fluticasone propionate alone salmeterol/fluticasone propionate combination adult moderate persistent asthma</brief_summary>
	<brief_title>SERETIDE 100/50 bd ( Twice Daily ) Versus FLIXOTIDE 100 bd As Initial Maintenance Therapy In Moderate Asthma In Adults</brief_title>
	<detailed_description>A multicentre randomise , double-blind , parallel-group study compare salmeterol/fluticasone propionate combination ( SERETIDETM DISKUSTM 50/100 ) 50/100µg one inhalation twice daily fluticasone propionate ( FLIXOTIDETM DISKUSTM 100 ) 100µg one inhalation twice daily initial maintenance therapy 12 week adults persistent moderate asthma</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Fluticasone Propionate , Salmeterol Xinafoate Drug Combination</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Inclusion criterion : male female ≥ 18 documented history asthma reversibility FEV1 PEF ≥ 12 % ( post 400µg salbu ) moderate asthma ( daily symptom , daily rescue use , PEF = 6080 % predict value ) naive ≥ 4weeksfree ICS ( inhaled corticosteroid ) Exclusion criterion : respiratory disorder FEV1 &lt; 60 % predict exacerbation/respiratory infection ≤ 4 week oral/parenteral/depot corticosteroid ≤ 6 month LABA/oral β2 agonist/ ALT/ theophylline ≤ 4 week smoker former smoker ≥ 5 pack year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>persistent</keyword>
	<keyword>moderate</keyword>
	<keyword>asthma</keyword>
	<keyword>adult</keyword>
	<keyword>Initial</keyword>
	<keyword>Maintenance</keyword>
	<keyword>Therapy</keyword>
</DOC>